Hepatitis Monthly

Published by: Kowsar

Acetyl-L-Carnitine Supplementation During HCV Therapy With Pegylated Interferon-α 2b Plus Ribavirin: Effect on Work Performance; A Randomized Clinical Trial

Giulia Malaguarnera 1 , Manuela Pennisi 2 , Caterina Gagliano 3 , Marco Vacante 3 , Michele Malaguarnera 1 , 3 , * , Salvatore Salomone 1 , Filippo Drago 1 , Gaetano Bertino 4 , Filippo Caraci 5 , 6 , Giuseppe Nunnari 7 and Mariano Malaguarnera 3
Authors Information
1 Department of Clinical and Molecular Biomedicine, Section of Pharmacology and Biochemistry, University of Catania, Catania, Italy
2 Department of Neurosciences, University of Catania, Catania, Italy
3 The Great Senescence Research Center, University of Catania, Catania, Italy
4 Department of Internal Medicine and Systemic Diseases, University of Catania, Catania, Italy
5 Department of Educational Sciences, University of Catania, Catania, Italy
6 Institute for Research on Mental Retardation and Brain Aging, Troina, Italy
7 Department of Clinical and Molecular Biomedicine, Division of Infectious Diseases, University of Catania, Catania, Italy
Article information
  • Hepatitis Monthly: May 01, 2014, 14 (5); e11608
  • Published Online: May 5, 2014
  • Article Type: Research Article
  • Received: April 16, 2013
  • Revised: August 2, 2013
  • Accepted: September 25, 2013
  • DOI: 10.5812/hepatmon.11608

To Cite: Malaguarnera G, Pennisi M, Gagliano C, Vacante M, Malaguarnera M, et al. Acetyl-L-Carnitine Supplementation During HCV Therapy With Pegylated Interferon-α 2b Plus Ribavirin: Effect on Work Performance; A Randomized Clinical Trial, Hepat Mon. 2014 ; 14(5):e11608. doi: 10.5812/hepatmon.11608.

Abstract
Copyright © 2014, Kowsar Corp. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Patients and Methods
4. Results
5. Discussion
Acknowledgements
Footnotes
References
  • 1. Armstrong GL, Wasley A, Simard EP, McQuillan GM, Kuhnert WL, Alter MJ. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med. 2006; 144(10): 705-14[PubMed]
  • 2. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. The Lancet. 2001; 358(9286): 958-65
  • 3. Foster GR. Quality of life considerations for patients with chronic hepatitis C. J Viral Hepat. 2009; 16(9): 605-11[DOI][PubMed]
  • 4. Hadziyannis SJ, Koskinas JS. Differences in epidemiology, liver disease and treatment response among HCV genotypes. Hepatol Res. 2004; 29(3): 129-35[DOI][PubMed]
  • 5. Spiegel BM, Younossi ZM, Hays RD, Revicki D, Robbins S, Kanwal F. Impact of hepatitis C on health related quality of life: a systematic review and quantitative assessment. Hepatology. 2005; 41(4): 790-800[DOI][PubMed]
  • 6. Schaefer M, Capuron L, Friebe A, Diez-Quevedo C, Robaeys G, Neri S, et al. Hepatitis C infection, antiviral treatment and mental health: a European expert consensus statement. J Hepatol. 2012; 57(6): 1379-90[DOI][PubMed]
  • 7. Rebouche CJ. Carnitine function and requirements during the life cycle. FASEB J. 1992; 6(15): 3379-86[PubMed]
  • 8. Malaguarnera M. Carnitine derivatives: clinical usefulness. Curr Opin Gastroenterol. 2012; 28(2): 166-76[DOI][PubMed]
  • 9. Malaguarnera M, Vacante M, Bertino G, Neri S, Malaguarnera M, Gargante MP, et al. The supplementation of acetyl-L-carnitine decreases fatigue and increases quality of life in patients with hepatitis C treated with pegylated interferon-alpha 2b plus ribavirin. J Interferon Cytokine Res. 2011; 31(9): 653-9[DOI][PubMed]
  • 10. Malaguarnera M, Bella R, Vacante M, Giordano M, Malaguarnera G, Gargante MP, et al. Acetyl-L-carnitine reduces depression and improves quality of life in patients with minimal hepatic encephalopathy. Scand J Gastroenterol. 2011; 46(6): 750-9[DOI][PubMed]
  • 11. Malaguarnera M. Acetyl-L-carnitine in hepatic encephalopathy. Metab Brain Dis. 2013; 28(2): 193-9[DOI][PubMed]
  • 12. Malaguarnera M, Vacante M, Giordano M, Motta M, Bertino G, Pennisi M, et al. L-carnitine supplementation improves hematological pattern in patients affected by HCV treated with Peg interferon-alpha 2b plus ribavirin. World J Gastroenterol. 2011; 17(39): 4414-20[DOI][PubMed]
  • 13. World Medical Association declaration of Helsinki. Recommendations guiding physicians in biomedical research involving human subjects. JAMA. 1997; 277(11): 925-6[PubMed]
  • 14. Stuyver L, Wyseur A, van Arnhem W, Hernandez F, Maertens G. Second-generation line probe assay for hepatitis C virus genotyping. J Clin Microbiol. 1996; 34(9): 2259-66[PubMed]
  • 15. Simmonds P, Alberti A, Alter HJ, Bonino F, Bradley DW, Brechot C, et al. A proposed system for the nomenclature of hepatitis C viral genotypes. Hepatology. 1994; 19(5): 1321-4[PubMed]
  • 16. Knodell RG, Ishak KG, Black WC, Chen TS, Craig R, Kaplowitz N, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology. 1981; 1(5): 431-5[PubMed]
  • 17. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology. 1996; 24(2): 289-93[DOI][PubMed]
  • 18. Wessely S, Powell R. Fatigue syndromes: a comparison of chronic "postviral" fatigue with neuromuscular and affective disorders. J Neurol Neurosurg Psychiatry. 1989; 52(8): 940-8[PubMed]
  • 19. Krupp LB, LaRocca NG, Muir-Nash J, Steinberg AD. The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol. 1989; 46(10): 1121-3[PubMed]
  • 20. Wahlqvist P, Carlsson J, Stalhammar NO, Wiklund I. Validity of a Work Productivity and Activity Impairment questionnaire for patients with symptoms of gastro-esophageal reflux disease (WPAI-GERD)--results from a cross-sectional study. Value Health. 2002; 5(2): 106-13[DOI][PubMed]
  • 21. Reilly MC, Bracco A, Ricci JF, Santoro J, Stevens T. The validity and accuracy of the Work Productivity and Activity Impairment questionnaire--irritable bowel syndrome version (WPAI:IBS). Aliment Pharmacol Ther. 2004; 20(4): 459-67[DOI][PubMed]
  • 22. Malaguarnera M, Laurino A, Di Fazio I, Pistone G, Castorina M, Guccione N, et al. Neuropsychiatric effects and type of IFN-alpha in chronic hepatitis C. J Interferon Cytokine Res. 2001; 21(5): 273-8[DOI][PubMed]
  • 23. Modabbernia A, Poustchi H, Malekzadeh R. Neuropsychiatric and psychosocial issues of patients with hepatitis C infection: a selective literature review. Hepat Mon. 2013; 13(1)[DOI][PubMed]
  • 24. Ashrafi M, Modabbernia A, Dalir M, Taslimi S, Karami M, Ostovaneh MR, et al. Predictors of mental and physical health in non-cirrhotic patients with viral hepatitis: a case control study. J Psychosom Res. 2012; 73(3): 218-24[DOI][PubMed]
  • 25. Malaguarnera M, Vicari E, Calogero A, Cammalleri L, Di Fazio I, Gargante MP, et al. Sexual dysfunction in chronic hepatitis C virus patients treated with interferon alpha and ribavirin. J Interferon Cytokine Res. 2008; 28(10): 603-9[DOI][PubMed]
  • 26. Rampello L, Vecchio I, Malaguarnera M, Rampello L. Parkinsonism with cognitive impairment. Acta Medica Mediterranea. 2012; 28: 123
  • 27. Caraci F, Bosco P, Leggio GM, Malaguarnera M, Drago F, Bucolo C, et al. Clinical pharmacology of novel anti-Alzheimer disease modifying medications. Curr Top Med Chem. 2013; 13(15): 1853-63[PubMed]
  • 28. Poynard T, Cacoub P, Ratziu V, Myers RP, Dezailles MH, Mercadier A, et al. Fatigue in patients with chronic hepatitis C. J Viral Hepat. 2002; 9(4): 295-303[PubMed]
  • 29. Vacante M, Malaguarnera G, Pennisi M, Grosso G, Salomone S, Drago F, et al. Work Productivity and Activity Impairment in Breast Cancer Patients Treated with Capecitabine. J Cancer Ther. 2013; 4(7): 1224-7
  • 30. Malaguarnera G, Pennisi M, Grosso G, Vacante M, Salomone S, Drago F, et al. Work Productivity and Activity Impairment in Colorectal Cancer Patients Treated with Capecitabine. J Cancer Ther. 2013; 4(7): 1198-202
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments